Barcelona, Spain – Most mutations which cause disease by swapping one amino acid out for another do so by making the protein less stable, according to a massive study of human protein variants published today in the journal Nature. Unstable proteins are more likely to misfold and degrade, causing them...
research News
DURHAM, N.C. – Autoimmune diseases are mysterious. It wasn’t until the 1950s that scientists realized that the immune system could harm the organs of its own body. Even today, the fundamental causes and inner workings of most autoimmune diseases remain poorly understood, limiting the treatment options for many of these...
Treatment-free remission (TFR) is feasible after 2 or more years of frontline nilotinib treatment in patients with chronic myeloid leukemia in chronic phase (CML-CP), reported researchers in a study published in Leukemia. Advances in the treatment of CML have improved outcomes for those with the disease; however, long-term treatment with tyrosine...
Memphis, Tenn – Compared to adult cancers, pediatric cancers often have distinctive genetic causes. This means there is an opportunity to develop pediatric-focused diagnostic strategies and treatments. Research by St. Jude Children’s Research Hospital published today in Nature Genetics clarifies the genomic landscape of pediatric acute myeloid leukemia (pAML). The...
ZURICH, Switzerland – Antiphospholipid syndrome is a systemic autoimmune disease associated with persistent antiphospholipid antibodies (aPL). It can cause thrombosis and pregnancy complications as well as non-thrombotic manifestations such as cardiac valve disease. Classification is important to help identify people to take part in research and ensures that similar disease...
Göttingen, Germany – In individuals with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), uric acid (UA) metabolism might be involved in activation of the complement system and thus serve as a contributory factor in the disease course, according to findings from a retrospective study published in the International Journal of Molecular...
PRINCETON, N.J. — UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced a licensing agreement with MEDAC GmbH to develop a next-generation novel mitomycin-based formulation for urothelial cancers. UGN-103, UroGen’s RTGel® technology combined with medac’s licensed mitomycin, is a...
Los Angeles, Calif. – Acute lymphoblastic leukemia (ALL), the most common childhood cancer, especially affects children of Hispanic/Latino origin in the United States. They are 30-40% more likely to get ALL than non-Hispanic white children, but the exact genetic basis and cause of that increased risk are unknown. Now, a...
Researchers at the Keck School of Medicine of the University of Southern California (USC) have identified a key mechanism that causes chromosomes within blood cells to break—an occurrence that marks the first step in the development of human lymphoma. The study provides researchers with the clearest insight yet into why...
Los Angeles, Calif. – The California Institute for Regenerative Medicine has awarded a $6 million grant to USC investigators pioneering a new first-of-its-kind genetic therapy for glioblastoma, a severe form of brain cancer. The treatment would be the first gene therapy for glioblastoma to use a novel, more precise delivery...